Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low arginine linked to SFTS

Li X-K et al. Sci Transl Med. doi: 10.1126/scitranslmed.aat4162

Key clinical point: Low arginine bioavailability was associated with increased risk for severe fever with thrombocytopenia syndrome (SFTS) fatality.

Major finding: Arginine bioavailability had an area under the receiver operating curve of 0.713 for predicting fatality.

Study details: A prospective cohort metabolomics study of 242 serum samples from patients with and without SFTS and a randomized, double-blind, placebo-controlled clinical trial of 113 patients given intravenous arginine supplementation or vehicle alone, in conjunction with supportive care.

Disclosures: The study was partially funded by a Bayer Investigator Award; Dr. Li and coauthors reported no other conflicts of interest.

Read the article here.


Li X-K et al. Sci Transl Med. doi: 10.1126/scitranslmed.aat4162.